This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Mixed Results for Pfizer Combo Pill

Shares of Pfizer (PFE - Get Report) skidded Tuesday after the pharmaceutical company issued mixed test results for a new drug to improve heart health.

The experimental drug lowers bad cholesterol and raises good cholesterol, but it also elevates blood pressure, according to preliminary results of a late-stage clinical trial.

By mid-afternoon, Pfizer's stock was off 74 cents, or 2.7%, to $26.45 on trading that was 50% higher than the average daily volume for the past three months.

The experimental drug combines Lipitor with the investigational compound torcetrapib. Pfizer is counting heavily on this combination pill, which features the bad-cholesterol-lowering power of Lipitor and the good-cholesterol-raising ability of torcetrapib.

Pfizer tested the combination pill vs. Lipitor in patients with heterozygous familial hypercholesterolemia -- a high level of bad cholesterol and a high risk of early heart disease. The combination pill raised good cholesterol by 56% and lowered bad cholesterol by 27% vs. patients taking only Lipitor. The study will be presented Nov. 15 at the American Heart Association's annual scientific convention in Chicago.

However, the combination pill also raised blood pressure by an average of about two millimeters vs. patients taking Lipitor. Systolic blood pressure, the upper number in a blood-pressure reading, reflects pressure of blood in arteries when the heart contracts. The lower number -- diastolic blood pressure -- measures pressure in arteries when the heart relaxes between beats.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
PFE $35.68 0.92%
AAPL $122.53 -0.69%
FB $95.70 0.43%
GOOG $625.00 -0.48%
TSLA $263.97 -0.32%


Chart of I:DJI
DOW 17,727.14 +96.87 0.55%
S&P 500 2,103.67 +10.42 0.50%
NASDAQ 5,100.8590 +11.6530 0.23%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs